Davita Inc vs Huntington Ingalls Industries Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Huntington Ingalls Industries Inc trades at $265.12 (market cap $10.44B). The key difference: Davita Inc and Huntington Ingalls Industries Inc are close in size by market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Huntington Ingalls Industries Inc for 28 Days on average.
| DVA | HII | |
|---|---|---|
Market Cap | $11.29B | $10.44B |
Volume | 582,204 | 440,462 |
Sector | Health | Industrials |
52-Week High | $240.96 | $453.73 |
52-Week Low | $103.87 | $257.05 |
Typical Hold Time | 113 Days | 28 Days |
Enterprise Value | $24.01B | $13.37B |
Dividend Yield | — | 2.08% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
HII trades at $260.67, down 1.17% with bearish technical signals but strong fundamentals. The company shows consistent earnings beats, with Q2 2026 EPS of $5.27 exceeding expectations by 39%. Recent contract wins including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders provide substantial revenue visibility. Valuation metrics appear reasonable with P/E of 15.78 and P/S of 0.79, while profitability metrics show ROE of 12.97% and net margin of 5.01%.
The investment case balances strong defense contracting fundamentals against technical weakness. Analyst consensus targets $363.67 (39% upside) with 40.7% buy ratings, though technical indicators show bearish momentum. Key risks include execution on large contracts and defense budget uncertainties, while catalysts include continued contract wins and autonomous technology expansion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →